搜索结果\"荧光显微镜”搜索结果适用产品信息8 /1～58 num产品名称A558AcidSensor Labeling Kit – Endocytic Internalization Assay应用pH Sensor Labeling Kit产品名称L264LysoPrime Deep Red - 高特异性和pH抗性应用溶酶体染色试剂（深红色）产品名称L265pHLys Red - 溶酶体酸性pH检测应用溶酶体酸性pH检测产品名称L267脂质过氧化探针-BDP 581/591 C11-应用脂质过氧化测定产品名称UP01葡萄糖摄取测定试剂盒-蓝色应用葡萄糖摄取能力测定产品名称UP02葡萄糖摄取测定试剂盒-绿色应用葡萄糖摄取能力测定产品名称UP03葡萄糖摄取测定试剂盒-红色应用葡萄糖摄取能力测定产品名称UP06葡萄糖摄取测定试剂盒-绿色应用葡萄糖摄取能力测定候选产品3 有用信息的搜索结果没有匹配的。Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-魏B pathway AbstractCa2+/calmodulin-dependent protein kinase II (CaMKII) and nuclear factor-kappa B (NF-魏B) play crucial roles in pathogenesis of doxorubicin (DOX)-induced cardiomyopathy. Their activities are regulated by intracellular Ca2+. We hypothesized that blockade of L-type Ca2+ channel (LTCC) could attenuate DOX-induced cardiomyopathy by regulating CaMKII and NF-魏B. DOX activated CaMKII and NF-魏B through their phosphorylation and increased cleaved caspase 3 in cardiomyocytes. Pharmacological blockade or gene knockdown of LTCC by nifedipine or small interfering RNA, respectively, suppressed DOX-induced phosphorylation of CaMKII and NF-魏B and apoptosis in cardiomyocytes, accompanied by decreasing intracellular Ca2+ concentration. Autocamtide 2-related inhibitory peptide (AIP), a selective CaMKII inhibitor, inhibited DOX-induced phosphorylation of NF-魏B and cardiomyocyte apoptosis. Inhibition of NF-魏B activity by ammonium pyrrolidinedithiocarbamate (PDTC) suppressed DOX-induced cardiomyocyte apoptosis. DOX-treatment (18鈥塵g/kg via intravenous 3 injections over 1 week) increased phosphorylation of CaMKII and NF-魏B in mouse hearts. Nifedipine (10鈥塵g/kg/day) significantly suppressed DOX-induced phosphorylation of CaMKII and NF-魏B and cardiomyocyte injury and apoptosis in mouse hearts. Moreover, it attenuated DOX-induced left ventricular dysfunction and dilatation. Our findings suggest that blockade of LTCC attenuates DOX-induced cardiomyocyte apoptosis via suppressing intracellular Ca2+ elevation and activation of CaMKII-NF-魏B pathway. LTCC blockers might be potential therapeutic agents against DOX-induced cardiomyopathy. IntroductionDoxorubicin (DOX) is an anthracycline antibiotic, which is widely used and efficacious chemotherapeutic drug for hematological malignancies and solid tumors. However, it has dose-dependent cardiotoxicity such as loss of cardiomyocytes and cardiac dysfunction, thereby limiting its clinical use1. DOX-induced cardiomyopathy has poor prognosis compared with dilated cardiomyopathy or ischemic cardiomyopathy2. Therefore, the establishment of effective therapeutic strategy for DOX-induced cardiomyopathy is urgently needed.Cardiomyocyte death such as apoptosis is a critical process implicated in DOX-induced cardiomyopathy3,4. A number of studies have suggested the molecular mechanisms of this disease state, including alteration of transcription by topoisomerase II5, mitochondrial iron accumulation6, oxidative stress such as lipid peroxidation7 and protein nitrosylation8, mitochondrial dysfunction9, and Ca2+ handling abnormality10,11. However, the fundamental mechanism underlying DOX-induced cardiomyocyte apoptosis remains to be fully elucidated.Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine-specific protein kinase, which is intimately involved in signaling cascades of cardiomyocyte survival and death12. A recent evidence suggests that activation of CaMKII critically mediates DOX-induced cardiomyocyte death and cardiac dysfunction13. As its name implies, CaMKII activity is dependent of intracellular Ca2+鈥?sup>14. Among potential sources of intracellular Ca2+, L-type Ca2+ channel (LTCC) is a major contributor to intracellular Ca2+ in cardiomyocytes15,16. To date, amlodipine, a LTCC blocker, has been reported to attenuate DOX-induced cardiomyocyte apoptosis in vitro by unknown mechanism17. In addition, nifedipine, another LTCC blocker, is known to inhibit pathological cardiac hypertrophy by suppressing CaMKII activity in cardiomyocytes18. These findings raise a possibility that blockade of LTCC exerts a protective role against DOX-induced cardiomyopathy by suppressing CaMKII-mediated cardiomyocyte apoptosis.Nuclear factor-kappa B (NF-魏B) is a transcriptional factor regulating genes associated with stress responses including apoptosis19. Several studies have demonstrated that NF-魏B is a critical mediator of DOX-induced cardiotoxicity20,21. NF-魏B is composed of multiple subunits such as RelA (p65), RelB, c-Rel, NF-kB1 (p50) and NF-魏B2 (p52) and phosphorylation of p65 promotes NF-魏B activity22,23. Although, importantly, NF-kB activity is also known to be regulated by intracellular Ca2+鈥?sup>24, no study has ever been performed to specifically examine the link between LTCC and NF-魏B in cardiomyocytes.A large number of animal experiments regarding DOX-induced cardiomyopathy have been performed by using a model of high-dose DOX treatment. This model is characterized by not only acute cardiotoxicity and cardiac dysfunction but also severe extra-cardiac phenotypes including malaise, anorexia, body weight loss, and non-cardiac death, resulting in conflicting interpretations with cardiac phenotype25 and leading to discrepant findings between animal experiment and clinical setting. Recently, a novel murine model of a low-dose DOX mimicking human DOX-induced cardiomyopathy has been reported, which causes modest but progressive cardiac dysfunction without severe non-cardiac effects25,26. This model is thought to be ideal for in vivo experiment regarding DOX-induced cardiomyopathy.The present study aimed to determine whether blockade of LTCC attenuates DOX-induced cardiomyocyte apoptosis by suppressing intracellular Ca2+ levels and activities of CaMKII and NF-魏B and whether it could ameliorate DOX-induced cardiomyopathy by using a low-dose DOX-treated model.ResultsDOX induced phosphorylation of CaMKII and NF-魏B and increased cleaved caspase 3 in cardiomyocytes in vitroFirst, we examined the effect of doxorubicin (DOX) on regulation of CaMKII and NF-魏B in neonatal rat ventricular myocytes (NRVMs). DOX increased phosphorylated CaMKII, an active form of CaMKII, in NRVMs in a dose-dependent manner with no significant changes in total CaMKII protein levels (Fig.聽1a,b). Whereas DOX slightly, but not significantly, decreased NF-魏B p65 protein levels, it increased phosphorylated NF-魏B p65, an active form of NF-魏B p65, in a dose-dependent manner (Fig.聽1a,c). Consistent with phosphorylation of CaMKII and NF-魏B p65, DOX increased cleaved caspase 3 protein levels in NRVMs (Fig.聽1a,d). Moreover, DOX-induced phosphorylation of CaMKII and NF-魏B p65 and increase in cleaved caspase 3 were time-dependent (Supplementary Fig.聽1a鈥揹). These data indicate that activation of CaMKII and NF-魏B is intimately involved in DOX-induced apoptosis in cardiomyocytes.Figure 1DOX induced phosphorylation of CaMKII and NF-魏B and increased cleaved caspase 3 in cardiomyocytes in a dose-dependent manner. (a) Representative immunoblots of CaMKII, phosphorylated CaMKII, NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in cultured neonatal rat ventricular myocytes (NRVMs) treated with indicated concentrations of DOX. (b鈥?b>d) Quantitative analysis of phosphorylated CaMKII, phosphorylated NF-魏B, and cleaved caspase 3 in NRVMs treated with indicated concentration of DOX (n鈥?鈥?). The experiment was conducted 2 times. *P鈥?lt;鈥?.05: post-hoc Tukey鈥檚 comparison test.Full size imageBlockade of LTCC suppressed DOX-induced phosphorylation of CaMKII and NF-魏B and increases in cleaved caspase 3 in cardiomyocytesNext, we investigated the effect of L-type Ca2+ channel (LTCC) on DOX-induced activation of CaMKII and NF-魏B. DOX increased phosphorylated LTCC, its active form, in NRVMs (Supplementary Fig.聽2). Nifedipine (1鈥壩糓, 24鈥塰) suppressed DOX-induced phosphorylation of CaMKII and NF-魏B p65 in cardiomyocytes with no significant changes of their expression levels (Fig.聽2a鈥揷). Nifedipine attenuated DOX-induced increases in cleaved caspase 3 (Fig.聽2a,d). Amlodipine (1鈥壩糓, 24鈥塰), another LTCC channel blocker, also attenuated DOX-induced phosphorylation of CaMKII and NF-魏B p65 and increases in cleaved caspase 3 (Supplementary Fig.聽3a鈥揹). To evaluate the direct effects of LTCC on CaMKII and NF-魏B, we transduced small interfering RNA (siRNA) for LTCC into cardiomyocytes. Transduction of siRNA significantly decreased LTCC expression levels in cardiomyocytes (Supplementary Fig.聽4). Downregulation of LTCC suppressed DOX-induced phosphorylation of CaMKII and NF-魏B p65 (Fig.聽2e鈥揼). It also attenuated DOX-induced increases in cleaved caspase 3 (Fig.聽2e,h). These data indicate that LTCC plays a crucial role in DOX-induced activation of CaMKII and NF-魏B and apoptosis in cardiomyocytes.Figure 2Blockade of LTCC suppressed DOX-induced phosphorylation of CaMKII and NF-魏B and increases in cleaved caspase 3 in cardiomyocytes. (a) Representative immunoblots of CaMKII, phosphorylated CaMKII, NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in NRVMs treated with or without nifedipine (Nif, 1鈥壩糓) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰our (n鈥?鈥?). The experiment was conducted 3 times. (b鈥?b>d) Quantitative analysis of phosphorylated CaMKII, phosphorylated NF-魏B, and cleaved caspase 3 in each group (n鈥?鈥?). (e) Representative immunoblots of CaMKII, phosphorylated CaMKII, NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in NRVMs treated with indicated small interfering RNA (siRNA) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰our (n鈥?鈥?). (f鈥?b>h) Quantitative analysis of phosphorylated CaMKII, phosphorylated NF-魏B, and cleaved caspase 3 in each group (n鈥?鈥?). The experiment was conducted 3 times. *P鈥?lt;鈥?.05, **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageBlockade of LTCC attenuated DOX-induced cardiomyocyte apoptosisWe investigated the role of LTCC on cardiomyocyte apoptosis evaluated by TUNEL staining. Both nifedipine (Fig.聽3a,b) and amlodipine (Supplementary Fig.聽3e) significantly attenuated DOX-induced cardiomyocyte apoptosis. They suppressed DOX-induced LDH release, a marker of cell death, from NRVMs (Fig.聽3c and Supplementary Fig.聽3f). In addition, downregulation of LTCC by siRNA also ameliorated DOX-induced cardiomyocyte apoptosis (Fig.聽3a,b) and LDH releases in cardiomyocytes (Fig.聽3c).Figure 3Blockade of LTCC attenuated DOX-induced cardiomyocyte apoptosis. (a,b) Apoptosis evaluated by TUNEL staining in NRVMs treated with nifedipine (Nif, 1鈥壩糓) or siRNA for LTCC (1鈥塶M) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours (n鈥?鈥?鈥?). The experiment was conducted 3 times. Arrows indicate TUNEL-positive cells. (c) LDH release, a marker of cell death, evaluated by LDH cytotoxicity assay in NRVMs treated with nifedipine (Nif) or siRNA for LTCC in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours (n鈥?鈥?鈥?). The experiment was conducted 3 times. **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageBlockade of LTCC attenuated DOX-induced elevation of intracellular Ca2+ levels in cardiomyocytesTo investigate whether intracellular Ca2+ levels are associated with cardiomyocyte death in DOX-induced cardiotoxicity, we measured resting intracellular Ca2+ concentration by Fura-2 fluorometry (Fig.聽4a). DOX treatment increased resting intracellular Ca2+ concentration in NRVMs, which was significantly suppressed by either nifedipine or amlodipine (Fig.聽4b,c Supplementary Fig.聽3g). Downregulation of LTCC by transduction of siRNA also attenuated DOX-induced elevation of resting intracellular Ca2+ concentration at the same level as nifedipine (Fig.聽4b,c). Furthermore, we investigated whether intracellular Ca2+ levels was intimately involved in CaMKII activation. 1,2-Bis (2-aminophenoxy) ethane-N,N,N鈥?N鈥?tetraacetic acid (BAPTA, 2鈥壩糓, 24鈥塰), an intracellular Ca2+ chelator, significantly suppressed DOX-induced phosphorylation of CaMKII (Fig.聽4d,e). These data indicate that LTCC-related intracellular Ca2+ accumulation induces CaMKII activation in NRVMs treated with DOX.Figure 4Blockade of LTCC attenuated DOX-induced elevation of intracellular Ca2+ levels in cardiomyocytes. (a) The resting levels of intracellular Ca2+ concentration in NRVMs were evaluated by fura-2 fluorometry. (b) A representative recording of fura-2 fluorometry in NRVMs treated with nifedipine (Nif) or siRNA for LTCC in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours. (c) The resting levels of intracellular Ca2+ were expressed as percentages by assigning the levels of intracellular Ca2+ obtained with ionomycin in the presence and absence of extracellular Ca2+, to be 100% and 0%, respectively. Cap-tipped lines indicate intracellular Ca2+ levels (n鈥?鈥?鈥?). (d) Representative immunoblots of CaMKII, phosphorylated CaMKII, and GAPDH in NRVMs treated with or without BAPTA (2鈥壩糓) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰our (n鈥?鈥?). (e) Quantitative analysis of phosphorylated CaMKII in each group (n鈥?鈥?). The experiment was conducted 2 times. **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageCaMKII positively regulated DOX-induced cardiomyocyte apoptosis by activating NF-魏BTo elucidate molecular mechanisms of DOX-induced cardiomyocyte apoptosis, we investigated the involvement of CaMKII in regulation of NF-魏B in DOX-treated cardiomyocytes. Autocamtide 2-related inhibitory peptide (AIP, 10鈥壩糓, 24鈥塰), a selective inhibitor of CaMKII, significantly decreased phosphorylation of CaMKII in DOX-treated NRVMs (Fig.聽5a,b). Importantly, AIP attenuated DOX-induced phosphorylation of NF-魏B p65 without affecting its protein levels (Fig.聽5a,c). Consistent with phosphorylation of NF-魏B p65, DOX induced NF-魏B translocation to nucleus and AIP significantly suppressed it (Supplementary Fig.聽5a,b). In addition, AIP decreased cleaved caspase-3 (Fig.聽5a,d) and the number of TUNEL positive cardiomyocytes after DOX treatment (Fig.聽5e). These data indicate that CaMKII is a positive regulator of NF-魏B activity and cardiomyocyte apoptosis. There are several CaMKII isoforms including CaMKII伪, CaMKII尾, CaMKII未, and CaMKII未. Among them, CaMKII未 is a major isoform in the heart. We investigated the role of CaMKII未 in NF-kB phosphorylation by using small interfering RNA. Knockdown of CaMKII未 decreased phosphorylation of NF-魏B (Supplementary Fig.聽6a鈥揹).Figure 5CaMKII positively regulated DOX-induced cardiomyocyte apoptosis by activating NF-魏B. (a) Representative immunoblots of CaMKII, phosphorylated CaMKII, NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in NRVMs treated with or without AIP (10鈥壩糓, 24鈥塰) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours (n鈥?鈥?鈥?). (b鈥?b>d) Quantitative analysis of phosphorylated CaMKII, phosphorylated NF-魏B, and cleaved caspase 3 in each group (n鈥?鈥?鈥?). The experiment was conducted 3 times. (e) Apoptosis evaluated by TUNEL staining in each group (n鈥?鈥?). The experiment was conducted 2 times. (f) Representative immunoblots of NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in NRVMs treated with or without PDTC (100鈥壩糓, 24鈥塰) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours (n鈥?鈥?鈥?). (g鈥?b>i) Quantitative analysis of phosphorylated NF-魏B and cleaved caspase 3 in NRVMs treated with or without PDTC (100鈥壩糓, 24鈥塰) in the presence or absence of DOX (10鈥壩糓) for 24鈥塰ours (n鈥?鈥?鈥?). The experiment was conducted 2 times. (j) Apoptosis evaluated by TUNEL staining in each group (n鈥?鈥?). The experiment was conducted 2 times. *P鈥?lt;鈥?.05, **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageNext, we investigated whether CaMKII regulates other factors known to be related to apoptosis. DOX induced phosphorylation of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and c-jun N-terminal kinase (JNK) and increased p53 protein levels, but AIP did not change them (Supplementary Fig.聽7a鈥揺). Furthermore, we evaluated signaling molecules involved in mitochondrial function, autophagy, and endoplasmic reticulum (ER) stress. Although DOX decreased mitochondrial transcription factor A (TFAM), PTEN-induced kinase 1 (PINK1), and C/EBP homologous protein (CHOP) and increased phosphorylation of Drp1, AIP did not affect these changes (Supplementary Fig.聽7f鈥搃,l). Both DOX and AIP did not affect Parkin and LC3-II (Supplementary Fig.聽7f,j,k). These data suggest that NF-魏B is a selective target of CaMKII in DOX-treated cardiomyocytes.Ammonium pyrrolidinedithiocarbamate (PDTC, 100鈥壩糓, 24鈥塰), a NF-魏B inhibitor, significantly inhibited DOX-induced phosphorylation of NF-魏B (Fig.聽5f,g). It attenuated DOX-induced increases in cleaved caspase 3 (Fig.聽5f,h) and the number of TUNEL-positive NRVMs (Fig.聽5i). Taken together, CaMKII mediates DOX-induced cardiomyocyte apoptosis by activating NF-魏B.Blockade of LTCC suppressed CaMKII-NF-魏B pathway in DOX-treated hearts in vivo Next, we investigated the role of LTCC in DOX-treated hearts. Mice were treated with PBS or DOX (18鈥塵g/kg via 3 intravenous injections over 1 week) with or without a subpressor dose of nifedipine (10鈥塵g/kg/day) (Supplementary Fig.聽8). DOX and nifedipine did not change body weight at 7 and 14 days after DOX injection (Supplementary Fig.聽9a). They did not alter food consumption (Supplementary Fig.聽9b) during 14 days and systolic blood pressure during at 14 days (Supplementary Fig.聽9c). In addition, DOX did not cause death.Nine days after DOX injection, DOX induced phosphorylation of CaMKII and NF-魏B p65 in the heart and nifedipine suppressed both of them (Fig.聽6a,b). We evaluated other cell death related factors such as ERK, JNK, Nox4, and p53 in the heart. DOX tended to decrease phosphorylation of ERK, but nifedipine did not affect them (Fig.聽6c,d). The expression levels of JNK, p53, and Nox4 and phosphorylation of JNK were not altered by DOX and nifedipine in the heart (Fig.聽6c,e,f,g). These data indicate that blockade of LTCC suppressed CaMKII-NF-魏B pathway in DOX-treated hearts.Figure 6Blockade of LTCC suppressed CaMKII-NF-kB pathway in DOX-treated hearts. (a) Representative immunoblots and quantitative analysis of CaMKII, phosphorylated CaMKII, and GAPDH in DOX (3 doses of DOX at 6鈥塵g/kg body weight every third day for 1 week) or control vehicle (phosphate-buffered saline: PBS) treated-C57B/6鈥塉 mouse hearts subjected to either nifedipine (Nif, 10鈥塵g/day/day) or saline for 9 days (n鈥?鈥?). (b) Representative immunoblots and quantitative analysis of NF-魏B, phosphorylated NF-魏B, cleaved caspase 3, and GAPDH in each group (n鈥?鈥?). The experiment was conducted 3 times. (c鈥?b>g) Representative immunoblotsa and quantitative analysis of ERK, phosphorylated ERK, JNK, phosphorylated JNK, Nox4, p53, and GAPDH in each group (n鈥?鈥?).Full size imageBlockade of LTCC ameliorated DOX-induced myocardial injury and apoptosis in miceWe assessed DOX-induced cardiomyocyte injury by number of cytoplasmic vaculolization and cardiomyocyte death by Billingham score. Nifedipine significantly prevented DOX-induced cardiomyocyte injury (Fig.聽7a,b) and cardiomyocyte death (Fig.聽7a,c). It suppressed DOX-induced apoptosis as evaluated by TUNEL staining in the heart (Fig.聽7d,e). Cardiomyocyte cross-sectional area was not altered by DOX or nifedipine (Fig.聽7f,g). Collagen volume fraction was increased in DOX-treated hearts, which was significantly attenuated by nifedipine (Fig.聽7h,i).Figure 7Blockade of LTCC ameliorated DOX-induced myocardial injury and apoptosis in mice. (a) HE stained section in DOX (3 doses of DOX at 6鈥塵g/kg body weight every third day for 1 week) or control vehicle (phosphate-buffered saline: PBS) treated-C57B/6鈥塉 mouse hearts subjected to either nifedipine (Nif, 10鈥塵g/day/day) or saline for 14 days. Arrows indicate cytoplasmic vacuolization and arrowheads indicate myofibrillar loss. (b) Cardiomyocyte injury as assessed by number of cytoplasmic vaculolization (n鈥?鈥?). (c) Cardiomyocyte death as assessed by Billingham score in the heart (n鈥?鈥?). (d) TUNEL stained heart section in each group. Arrow heads indicate TUNEL-positive nuclei. (e) The percentage of TUNEL-positive nuclei in the heart (n鈥?鈥?). (f) WGA-stained heart section in each group. (g) Cardiomyocyte hypertrophy as assessed by cross-sectional area in each group (n鈥?鈥?). (h) Masson-trichrome-stained heart section in each group. (i) Interstitial fibrosis as assessed by collagen volume in each group (n鈥?鈥?). *P鈥?lt;鈥?.05, **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageBlockade of LTCC attenuated DOX-induced cardiac dysfunction and loss of heart weight in miceWe evaluated cardiac function by echocardiography (Fig.聽8a). Heart rate was comparable in groups (Fig.聽8b). DOX-treated mice had greater left ventricular (LV) end-diastolic diameter (Fig.聽8c) and end-systolic diameter (Fig.聽8d) and lower fractional shortening (Fig.聽8e) and LV ejection fraction (Fig.聽8f) than control mice. Nifedipine attenuated these DOX-induced LV dilatation (Fig.聽8c,d) and dysfunction (Fig.聽8e,f). LV wall thicknesses were comparable in groups (Control鈥?鈥塖aline: 0.62鈥壜扁€?.02鈥塵m, Control鈥?鈥塏if: 0.57鈥壜扁€?.02鈥塵m, DOX鈥?鈥塖aline: 0.56鈥壜扁€?.01鈥塵m, DOX鈥?鈥塏if: 0.63鈥壜扁€?.02鈥塵m). DOX-treated mice showed lower whole heart weight and LV weight and nifedipine significantly ameliorated these decreases (Fig.聽8g,h).Figure 8Blockade of LTCC attenuated DOX-induced cardiac dysfunction and loss of heart weight in mice. (a) The representative echocardiographic images of DOX (3 doses of DOX at 6鈥塵g/kg body weight every third day for 1 week) or control vehicle (phosphate-buffered saline: PBS) treated-C57B/6鈥塉 mouse hearts subjected to either nifedipine (Nif, 10鈥塵g/day/day) or saline for 14 days. Long two-way arrows and short two-way arrows indicate left ventricular end-diastolic diameter (LVDd) and left ventricular end-systolic diameter (LVDs), respectively. (b鈥?b>f) Heart rate, LVDd and LVDs, fractional shortening, and LV ejection fraction measured by echocardiography at day14 in each group (n鈥?鈥?鈥?4). (g,h) Heart weight to tibial length (TL) ratio and LV weight to TL ratio in each group (n鈥?鈥?鈥?4). *P鈥?lt;鈥?.05, **P鈥?lt;鈥?.01: post-hoc Tukey鈥檚 comparison test.Full size imageDiscussionThe present study provided three novel findings. First, LTCC was a key regulator of intracellular Ca2+ and activation of CaMKII and NF-魏B in DOX-induced cardiomyocyte apoptosis. Second, CaMKII positively regulated NF-魏B activity in DOX-induced cardiomyocyte apoptosis. Finally the blockade of LTCC attenuated DOX-induced cardiomyopathy by suppressing CaMKII-NF-魏B pathway (Supplementary Fig.聽10). To our knowledge, the present study is the first report demonstrating the role of LTCC in DOX-induced cardiomyopathy and its downstream signaling.CaMKII, a serine/threonine-specific protein kinase, plays a central role in development of cardiac hypertrophy and failure12. A recent study has shown that activation of CaMKII mediates DOX-induced cardiomyocyte death including apoptosis and cardiomyopathy13. CaMKII is activated by an increase in intracellular Ca2+ concentration14. There are several sources of intracellular Ca2+ such as LTCCs coupled with Ca2+-induced Ca2+ release from the ryanodine receptor, T-type Ca2+ channel, transient receptor potential channel, and IP3 receptor channel27. Among them, LTCCs are the primary source of Ca2+ influx to initiate cardiac excitation-contraction coupling28,29. Ca2+ influx from LTCCs mediates intracellular signaling that underlie cardiac hypertrophy30,31. In addition, previous studies have shown that DOX increased Ca2+ concentration in cardiomyocytes10,11. In the present study, both pharmacological blockade and gene knockdown of LTCC suppressed DOX-induced intracellular Ca2+ elevation and CaMKII activation in cardiomyocytes. Although DOX did not affect the expression levels of LTCC, it significantly increased phosphorylation of LTCC (Supplementary Fig.聽2). These data suggest that intracellular Ca2+ levels regulated by LTCC is implicated in CaMKII activity in DOX-induced cardiotoxicity. The pathological role of LTCC in cardiovascular diseases, especially in cardiac hypertrophy, has been reported to be controversial32,33. Our results demonstrated a critical role of LTCC in CaMKII activity and a protective effect of its blockade against DOX-induced cardiomyopathy. Among 4 isoforms of CaMKII (伪, 尾, 未, and 纬 subunit), CaMKII未 is predominantly expressed in the heart34. Knockdown of CaMKII未 suppressed DOX-induced phosphorylation of NF-魏B (Supplementary Fig.聽6), indicating that CaMKII未 is a critical isoform mediating DOX-induced cardiotoxicity. However, further investigations are needed to determine the distinct role of other CaMKII isoforms in DOX-induced cardiotoxicity.NF-魏B is a multifunctional transcriptional factor, which is intimately involved in cardiomyocyte death20,35 and cardiac remodeling36. The present study demonstrated that DOX evoked NF-魏B activity, which was suppressed by blockade of LTCC (Figs聽2a,c, 6b). Inhibition of NF-魏B attenuated DOX-induced increases in cleaved caspase 3 and cardiomyocyte apoptosis (Fig.聽5I,j). Thus, the blockade of LTCC ameliorated DOX-induced cardiotoxicity probably due to the suppression of not only CaMKII but also NF-魏B. CaMKII is known to have several downstream targets such as histone deacetylase 4 (HDAC4) and nuclear factor of activated T cells (NFAT) in cardiac hypertrophy37, however, its downstream targets in DOX-induced cardiomyopathy have not been revealed yet. We here found that the inhibition of CaMKII activity by AIP, a selective CaMKII inhibitor, suppressed DOX-induced NF-魏B activation (Fig.聽5a,c). In addition, knockdown of CaMKII未 suppressed DOX-induced NF-魏B activation (Supplementary Fig.聽6). These findings suggest that CaMKII, especially CaMKII未, is a positive regulator of NF-魏B and CaMKII-NF-魏B axis critically mediates cardiomyocyte apoptosis in DOX-induced cardiotoxicity. There are several reports regarding association between NF-kB and apoptosis. Li et al. demonstrated that NF-魏B activation induced apoptosis through upregulation of PUMA38. In addition, it has been reported that NF-kB induces apoptosis via inflammation21. However, further investigation is required to determine precise mechanisms regulating phosphorylation of NF-kB by CaMKII.Mitochondrial function26, autophagy25, and ER stress39 are known to be implicated in DOX-induced cardiotoxicity. However, AIP did not affect DOX-induced changes of TFAM, PINK1, CHOP and phosphorylation of Drp1 (Supplementary Fig.聽7g鈥搃,l). Although phosphorylation of JNK40, ERKs/p53 signal41, and Nox442 was reported to be involved in DOX-induced cardiomyocyte apoptosis, our results demonstrated that AIP or nifedipine did not affect DOX-induced changes of these proteins (Fig.聽6c-g and Supplementary Fig.聽7a鈥揺). Thus, blockade of LTCC might attenuate DOX-induced cardiomyopathy by selectively suppressing CaMKII-NF-魏B axis.Interestingly, nifedipine attenuated not only apoptosis (Fig.聽7d,e) but also interstitial fibrosis (Fig.聽7h,i) in DOX-treated hearts. Nifedipine may primarily prevent apoptosis and secondarily attenuate reactive fibrosis in DOX-induced cardiomyopathy. In addition, it might directly act on non-cardiomyocytes such as fibroblasts.A low-dose DOX treatment did not affect body weight and food consumption. The heart treated with a low-dose DOX demonstrated LV dilatation, impaired LV dysfunction, loss of LV weight, and increases in cardiomyocyte injury, apoptosis, and interstitial fibrosis (Fig.聽7a鈥揺,h,i). These phenotypes are observed in human DOX-induced cardiomyopathy, indicating that a low-dose DOX model is equivalent to this disease in human. The beneficial effects of nifedipine shown in this study were not due to its blood pressure lowering effect or nutrition preserving effect because it did not alter blood pressure, body weight, and food consumption.In this study, we used nifedipine and amlodipine, which are most widely prescribed LTCC blockers for treatment of hypertension. Pleiotropic effects of these drugs can not be completely excluded. However, nifedipine and amlodipine similarly suppressed DOX-induced elevation of intracellular Ca2+ concentration and activation of CaMKII and NF-魏B in cardiomyocytes. Furthermore, gene knockdown of LTCC also significantly suppressed them. These findings based on different types of intervention in LTCC indicate that CaMKII and NF-魏B are downstream targets of LTCC-related intracellular Ca2+ in DOX-induced cardiomyopathy.In general, short-acting Ca2+ channel blockers are not recommended for LV dysfunction and heart failure because of their hypotensive potential. Long-acting Ca2+ channel blocker might be better for DOX-induced cardiomyopathy with LV dysfunction. Moreover, the continuous way of administration may overcome the hypotension issue.In conclusions, blockade of LTCC attenuates DOX-induced cardiomyocyte apoptosis by suppressing intracellular Ca2+ abnormalities and CaMKII-NF-魏B pathway. LTCC blocker protects the heart against DOX-induced cardiotoxicity in vivo by suppressing CaMKII-NF-魏B pathway. Therapeutic strategy designed to interfere with this pathway by LTCC blocker might be beneficial in DOX-induced cardiomyopathy.MethodsReagentsDoxorubicin (D1515), nifedipine (N7634), autocamtide 2-related inhibitory peptide (AIP, A4308), and ammonium pyrrolidinedithiocarbamate (PTCD, P8765) were purchased from sigma. Amlodipine (A2353) was purchased from Tokyo Chemical Industry. 1,2-Bis (2-aminophenoxy) ethane-N,N,N鈥?N鈥?tetraacetic acid (BAPTA, ab120503) was obtained from abcam.Primary culture of neonatal rat ventricular myocytesPrimary cultures of ventricular cardiac myocytes were prepared from 1-day-old Sprague-Dawley rats (Kyudo Inc, Japan). A cardiac myocyte-rich fraction was obtained by centrifugation through a discontinuous Percoll gradient as described previously43.siRNA and transfectionSilencing of L-type Ca2+ channel (LTCC) and CaMKII未 gene expressions in primary neonatal rat cardiomyocytes were achieved by the small interfering RNA (siRNA) technique. The sequences of the siRNA duplexes were selected from the coding regions of the target mRNAs. Silencer select siRNA specific to decrease the expression of rat LTCC and CaMKII未 mRNA were purchased from Themo Fisher Scientific. The sense strand of siRNA used to silence the rat LTCC gene (LTCC siRNA) and CaMKII未 gene (CaMKII未 siRNA) were CCUGCGAUAUGACAAUAGA, and GCAACUUAGUGGAAGGGAUTT, respectively. Transfection of cultured cardiomyocytes was carried out by Lipofectamine RNAiMAX (Themo Fisher Scientific) according to proposed protocol.Measurement of resting intracellular calcium concentration by Fura-2 fluorometryCardiomyocytes plated on 35-mm dishes were loaded with fura-2 by incubation in DMEM containing 5鈥壩糓 fura-2 acetoxymethylester (Dojindo Laboratories, Kumamoto, Japan) and 1鈥塵M at 37鈥壜癈 in a chamber containing 5% CO2 for 15鈥塵inutes, as described previously44,45. Probenecid was used to prevent extracellular leakage of fura-2 by inhibiting anion transporter. After fura-2 loading, the cells were equilibrated in HEPES-buffered saline (HBS; 10鈥塵M HEPES, pH 7.4, 135鈥塵M NaCl, 5鈥塵M KCl, 1鈥塵M, CaCl2, 1鈥塵M MgCl2, and 5.5鈥塵M D-glucose) at room temperature for 10鈥塵in before initiating the fluorometry. Changes in the fura-2 fluorescence ratio (excitation at 340 and 380鈥塶m; emission at 500鈥塶m) in the cell population were monitored as an indication of intracellular Ca2+ concentration using a frontsurface fluorometer (CAM230-OF2), as described previously44,45. The resting levels of intracellular Ca2+ levels were expressed as percentages by assigning the levels of intracellular Ca2+ obtained with ionomycin, (a calcium ionophore, LKT Laboratories, St. Paul, MN) in the presence and absence of intracellular and extracellular Ca2+, to be 100% and 0%, respectively. EGTA was used to chelate intracellular calcium. In addition, probenecid was used to prevent extracellular leakage of fura-2 by inhibiting anion transporter.Immunoblot analysesCardiomyocyte lysates and heart homogenates were prepared in RIPA lysis buffer containing Tris-HCl, NaCl, NP-40, sodium deoxycholae, and SDS. For immunoblot analyses, we used monoclonal antibodies against CaMKII (#4436, Cell Signaling Technology), NF-kB (#8242, Cell Signaling Technology), phospho-CaMKII (Thr286) (#12716, Cell Signaling Technology), phospho-NF-魏B (Ser536) (#3033, Cell Signaling Technology), cleaved caspase 3 (#9664, Cell Signaling Technology), phospho-JNK (Thr183/Tyr185) (#4668, Cell Signaling Technology), p53 (#32532, Cell Signaling Technology), CHOP (#5554, Cell Signaling Technology), PINK1 (ab75487, abcam), DRP1 (611112, BD Bioscience), phosphor-DRP1 (#4494), and GAPDH (sc32233, Santa Cruz Biotechnology), and polyclonal antibodies against ERK (#9102, Cell Signaling Technology), phospho-ERK (Thr202/Tyr204) (#9101, Cell Signaling Technology), JNK (#9252, Cell Signaling Technology), Nox4 (NB11058849, Novus), Parkin (ab15954, abcam), LTCC (#ACC-003, alomone labs), phospho LTCC (A010鈥?0, Badrilla), and mtTFAM (sc23588, Santa Cruz Biotechnology).ImmunostainingCardiomyocytes grown glass plate dish were washed 3 times with PBS. The cells were fixed with 4% paraformaldehyde and washed 3 times with PBS. The cells were then treated with 0.1% Triton X-100 for 15鈥塵inutes and washed 3 times with PBS. Cells were blocked with PBS containing 1% bovine serum albumin for 60鈥塵inutes and stained with antibodies as indicated.TUNEL stainingTUNEL staining was conducted as described46. Deparaffinized sections were incubated with proteinase K and DNA fragments were labeled with fluorescein-conjugated dTUP using in situ Apoptosis Detection kit (MK500, Takara). Nuclear density was determined by manual counting of DAPI-stained nuclei in 10 fields for each animal using a 40x objective.LDH release assayLactate dehydrogenase (LDH) release into the media from damaged cells were measured by LDH cytotoxicity assay kit (299鈥?0601, wako).Doxorubicin-induced cardiomyopathy modelTo create a mouse model mimicking human doxorubicin cardiomyopathy, 9 to 10-weeks-old C57BL/6鈥塉 mice were treated with 3 doses of DOX at 6鈥塵g/kg body weight intravenously via tail vein injections every third day for 1 week as described26. Continuous infusion of nifedipine (10鈥塵g/kg/day) or control vehicle delivery was conducted using a miniosmotic pump (model 2002, Alzet). Nifedipine was prepared at a concentration calculated to deliver an average of 10鈥塵g/kg/day during a 14-day infusion period. Control mice received pumps filled with vehicle (dimethyl sulfoxide) alone. Immunoblot analysis was conducted by using hearts at 9 days after starting saline or DOX injection. After 14 days, echocardiography was performed and then the heart was extracted for histological analysis (Supplementary Fig.聽4). All procedures involving animals and animal care protocols were approved by the Committee on Ethics of Animal Experiments of the Kyushu University Graduate School of Medicine and Pharmaceutical Sciences (A29鈥?90), and were performed in accordance with the Guideline for Animal Experiments of Kyushu University and the Guideline for the Care and Use of Laboratory Animals published by the US National Institutes of Health (revised in 2011).EchocardiographyUnder light anesthesia with 1鈥?% isoflurane, two-dimensional targeted M-mode images were obtained from the short axis view at the papillary muscle level using a Vevo 2100 ultrasonography system (Visual Sonics, Toronto, Canada) as previously described47. Fractional shortening is calculated from: %FS鈥?鈥塠(diastolic LV diameter鈥攕ystolic LV diameter)/diastolic LV diameter)鈥壝椻€?00]. LV wall thickness was calculated as average of interventricular septum thickness and posterior wall thickness.Histological analysesThe LV accompanied by the septum was cut into base and apex portions, fixed with 10% formalin and submitted for hematoxylin and eosin staining. Myocardial injury was evaluated by Billingham score and cytoplasmic vaculolization as previously reported48,49. Briefly, Billingham scores were based on the percentage of myocytes showing cytoplasmic vacuolization and/or myofibrillar loss, and graded from 0 to 3 as follows: 0, no damaged cells; 1, 1.5, 5鈥?5%; 2.0, 16鈥?5%; 2.5, 26鈥?5%; and 3, 35% damaged cells. Cytoplasmic vacuolization were assessed around 20 microscopic fields randomly selected in LVs per section, 3 sections from each mouse. Myocyte cross-sectional area was evaluated by mid-LV stained with wheat germ agglutinin (WGA) as described previously50. Collagen volume was determined by quantitative morphometry of tissue sections from the mid-LV stained with Masson鈥檚 trichrome as described previously51.Statistical analysisAll values are expressed as mean鈥壜扁€塖EM. Statistical analyses were performed using ANOVA followed by a post-hoc Tukey鈥檚 comparison test. P鈥?lt;鈥?.05 was considered to be statistically significant. All data generated or analysed during this study are included in this published article (and its supplementary information files). References1.Barrett-Lee, P. J. et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 20, 816鈥?27, https://doi.org/10.1093/annonc/mdn728 (2009).CAS聽 Article聽 PubMed聽 Google Scholar聽 2.Felker, G. M. et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 342, 1077鈥?084, https://doi.org/10.1056/NEJM200004133421502 (2000).CAS聽 Article聽 PubMed聽 Google Scholar聽 3.Kotamraju, S., Konorev, E. A., Joseph, J. Kalyanaraman, B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem. 275, 33585鈥?3592, https://doi.org/10.1074/jbc.M003890200 (2000).CAS聽 Article聽 PubMed聽 Google Scholar聽 4.Wang, L., Ma, W., Markovich, R., Chen, J. W. Wang, P. H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 83, 516鈥?22 (1998).CAS聽 Article聽 Google Scholar聽 5.Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 18, 1639鈥?642, https://doi.org/10.1038/nm.2919 (2012).CAS聽 Article聽 PubMed聽 Google Scholar聽 6.Ichikawa, Y. et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 124, 617鈥?30, https://doi.org/10.1172/JCI72931 (2014).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 7.Hrelia, S. et al. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 1567, 150鈥?56 (2002).CAS聽 Article聽 Google Scholar聽 8.Maejima, Y., Adachi, S., Morikawa, K., Ito, H. Isobe, M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol. 38, 163鈥?74, https://doi.org/10.1016/j.yjmcc.2004.10.012 (2005).CAS聽 Article聽 PubMed聽 Google Scholar聽 9.Lebrecht, D., Setzer, B., Ketelsen, U. P., Haberstroh, J. Walker, U. A. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 108, 2423鈥?429, https://doi.org/10.1161/01.CIR.0000093196.59829.DF (2003).CAS聽 Article聽 PubMed聽 Google Scholar聽 10.Sag, C. M., Kohler, A. C., Anderson, M. E., Backs, J. Maier, L. S. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 51, 749鈥?59, https://doi.org/10.1016/j.yjmcc.2011.07.016 (2011).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 11.Lebrecht, D., Kirschner, J., Geist, A., Haberstroh, J. Walker, U. A. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. Cardiovasc Pathol. 19, e167鈥?74, https://doi.org/10.1016/j.carpath.2009.06.006 (2010).CAS聽 Article聽 PubMed聽 Google Scholar聽 12.Anderson, M. E., Brown, J. H. Bers, D. M. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 51, 468鈥?73, https://doi.org/10.1016/j.yjmcc.2011.01.012 (2011).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 13.Zhang, T. et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 22, 175鈥?82, https://doi.org/10.1038/nm.4017 (2016).CAS聽 Article聽 PubMed聽 Google Scholar聽 14.De Koninck, P. Schulman, H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science. 279, 227鈥?30 (1998).ADS聽 Article聽 Google Scholar聽 15.Viola, H. M., Davies, S. M., Filipovska, A. Hool, L. C. L-type Ca(2+) channel contributes to alterations in mitochondrial calcium handling in the mdx ventricular myocyte. Am J Physiol Heart Circ Physiol. 304, H767鈥?75, https://doi.org/10.1152/ajpheart.00700.2012 (2013).CAS聽 Article聽 PubMed聽 Google Scholar聽 16.Er, F. et al. Impact of testosterone on cardiac L-type calcium channels and Ca2+ sparks: acute actions antagonize chronic effects. Cell Calcium. 41, 467鈥?77, https://doi.org/10.1016/j.ceca.2006.09.003 (2007).CAS聽 Article聽 PubMed聽 Google Scholar聽 17.Yamanaka, S. et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol. 41, 870鈥?78 (2003).CAS聽 Article聽 Google Scholar聽 18.Ago, T., Yang, Y., Zhai, P. Sadoshima, J. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload. J Cardiovasc Transl Res. 3, 304鈥?13, https://doi.org/10.1007/s12265-010-9182-x (2010).Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 19.Gordon, J. W., Shaw, J. A. Kirshenbaum, L. A. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108, 1122鈥?132, https://doi.org/10.1161/CIRCRESAHA.110.226928 (2011).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 20.Li, S., E, M. Yu, B. Adriamycin induces myocardium apoptosis through activation of nuclear factor kappaB in rat. Mol Biol Rep 35, 489鈥?94, https://doi.org/10.1007/s11033-007-9112-4 (2008).CAS聽 Article聽 PubMed聽 Google Scholar聽 21.Guo, R. M. et al. Activation of the p38 MAPK/NF-kappaB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep. 8, 603鈥?08, https://doi.org/10.3892/mmr.2013.1554 (2013).Article聽 PubMed聽 Google Scholar聽 22.Hamid, T. et al. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 89, 129鈥?38, https://doi.org/10.1093/cvr/cvq274 (2011).ADS聽 CAS聽 Article聽 PubMed聽 Google Scholar聽 23.Shen, Y. et al. Interleukin-17-induced expression of monocyte chemoattractant protein-1 in cardiac myocytes requires nuclear factor kappaB through the phosphorylation of p65. Microbiol Immunol. 61, 280鈥?86, https://doi.org/10.1111/1348-0421.12495 (2017).CAS聽 Article聽 PubMed聽 Google Scholar聽 24.Tabary, O. et al. Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells. Cell Signal. 18, 652鈥?60, https://doi.org/10.1016/j.cellsig.2005.06.004 (2006).CAS聽 Article聽 PubMed聽 Google Scholar聽 25.Li, D. L. et al. Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation. 133, 1668鈥?687, https://doi.org/10.1161/CIRCULATIONAHA.115.017443 (2016).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 26.Hull, T. D. et al. Heme oxygenase-1 regulates mitochondrial quality control in the heart. JCI insight. 1, e85817, https://doi.org/10.1172/jci.insight.85817 (2016).Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 27.Molkentin, J. D. Dichotomy of Ca2+ in the heart: contraction versus intracellular signaling. J Clin Invest. 116, 623鈥?26, https://doi.org/10.1172/JCI27824 (2006).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 28.Benitah, J. P., Alvarez, J. L. Gomez, A. M. L-type Ca(2+) current in ventricular cardiomyocytes. J Mol Cell Cardiol. 48, 26鈥?6, https://doi.org/10.1016/j.yjmcc.2009.07.026 (2010).CAS聽 Article聽 PubMed聽 Google Scholar聽 29.Bers, D. M. Cardiac excitation-contraction coupling. Nature. 415, 198鈥?05, https://doi.org/10.1038/415198a (2002).ADS聽 CAS聽 Article聽 PubMed聽 Google Scholar聽 30.Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93, 215鈥?28 (1998).CAS聽 Article聽 Google Scholar聽 31.Chawla, S., Hardingham, G. E., Quinn, D. R. Bading, H. CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. Science. 281, 1505鈥?509 (1998).ADS聽 CAS聽 Article聽 Google Scholar聽 32.Keung, E. C. Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ Res. 64, 753鈥?63 (1989).CAS聽 Article聽 Google Scholar聽 33.Goonasekera, S. A. et al. Decreased cardiac L-type Ca(2)(+) channel activity induces hypertrophy and heart failure in mice. J Clin Invest. 122, 280鈥?90, https://doi.org/10.1172/JCI58227 (2012).CAS聽 Article聽 PubMed聽 Google Scholar聽 34.Zhang, T. Brown, J. H. Role of Ca2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc Res 63, 476鈥?86, https://doi.org/10.1016/j.cardiores.2004.04.026 (2004).CAS聽 Article聽 PubMed聽 Google Scholar聽 35.Wei, C., Li, L., Kim, I. K., Sun, P. Gupta, S. NF-kappaB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress. Free Radic Res. 48, 282鈥?91, https://doi.org/10.3109/10715762.2013.865839 (2014).CAS聽 Article聽 PubMed聽 Google Scholar聽 36.Kawano, S. et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol. 291, H1337鈥?344, https://doi.org/10.1152/ajpheart.01175.2005 (2006).CAS聽 Article聽 PubMed聽 Google Scholar聽 37.Backs, J., Song, K., Bezprozvannaya, S., Chang, S. Olson, E. N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 116, 1853鈥?864, https://doi.org/10.1172/JCI27438 (2006).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 38.Li, D., Li, J., An, Y., Yang, Y. Zhang, S. Q. Doxorubicin-induced apoptosis in H9c2 cardiomyocytes by NF-kappaB dependent PUMA upregulation. Eur Rev Med Pharmacol Sci. 17, 2323鈥?329 (2013).CAS聽 PubMed聽 Google Scholar聽 39.Fu, H. Y. et al. Chemical Endoplasmic Reticulum Chaperone Alleviates Doxorubicin-Induced Cardiac Dysfunction. Circ Res 118, 798鈥?09, https://doi.org/10.1161/CIRCRESAHA.115.307604 (2016).CAS聽 Article聽 PubMed聽 Google Scholar聽 40.Yao, Y. et al. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway. Basic Res Cardiol. 107, 267, https://doi.org/10.1007/s00395-012-0267-3 (2012).CAS聽 Article聽 PubMed聽 Google Scholar聽 41.Liu, J., Mao, W., Ding, B. Liang, C. S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 295, H1956鈥?965, https://doi.org/10.1152/ajpheart.00407.2008 (2008).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 42.Li, J. Z., Yu, S. Y., Wu, J. H., Shao, Q. R. Dong, X. M. Paeoniflorin protects myocardial cell from doxorubicin-induced apoptosis through inhibition of NADPH oxidase. Can J Physiol Pharmacol. 90, 1569鈥?575, https://doi.org/10.1139/y2012-140 (2012).CAS聽 Article聽 PubMed聽 Google Scholar聽 43.Morisco, C. et al. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem. 276, 28586鈥?8597, https://doi.org/10.1074/jbc.M103166200 (2001).CAS聽 Article聽 PubMed聽 Google Scholar聽 44.Hirano, K., Hirano, M. Hanada, A. Involvement of STIM1 in the proteinase-activated receptor 1-mediated Ca2+ influx in vascular endothelial cells. J Cell Biochem. 108, 499鈥?07, https://doi.org/10.1002/jcb.22279 (2009).CAS聽 Article聽 PubMed聽 Google Scholar聽 45.Hirano, K. et al. Distinct Ca2+ requirement for NO production between proteinase-activated receptor 1 and 4 (PAR1 and PAR4) in vascular endothelial cells. J Pharmacol Exp Ther. 322, 668鈥?77, https://doi.org/10.1124/jpet.107.121038 (2007).CAS聽 Article聽 PubMed聽 Google Scholar聽 46.Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest. 111, 1463鈥?474, https://doi.org/10.1172/JCI17459 (2003).CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 47.Ikeda, M. et al. The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload. Sci Rep. 5, 15881, https://doi.org/10.1038/srep15881 (2015).ADS聽 CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 48.Bruynzeel, A. M. et al. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother Pharmacol. 58, 699鈥?02, https://doi.org/10.1007/s00280-006-0206-9 (2006).CAS聽 Article聽 PubMed聽 Google Scholar聽 49.Vacchi-Suzzi, C. et al. Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PloS One. 7, e40395, https://doi.org/10.1371/journal.pone.0040395 (2012).ADS聽 CAS聽 Article聽 PubMed聽 PubMed Central聽 Google Scholar聽 50.Matsushima, S. et al. Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling. J Clin Invest n 126, 3403鈥?416, https://doi.org/10.1172/JCI85624 (2016).Article聽 Google Scholar聽 51.Matsushima, S. et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation. 113, 1779鈥?786, https://doi.org/10.1161/CIRCULATIONAHA.105.582239 (2006).CAS聽 Article聽 PubMed聽 Google Scholar聽 Download referencesAcknowledgementsWe are very grateful to A. Hanada and M. Sato for technical support. We also appreciate the technical assistance from the Research Support Center, Faculty of Medical Sciences, Kyushu University. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Nos 25893005, 15H04815, and 17K09581) and Vascular Biology Innovation Conference (VBIC).Author informationAffiliationsDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, JapanSoichiro Ikeda,聽Kosuke Okabe,聽Masataka Ikeda,聽Akihito Ishikita,聽Tomonori Tadokoro,聽Nobuyuki Enzan,聽Taishi Yamamoto,聽Masashi Sada,聽Hiroko Deguchi聽 聽Hiroyuki TsutsuiDepartment of Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, JapanShouji MatsushimaDepartment of Health Sciences Fukuoka, International University of Health and Welfare, Okawa, JapanSachio MorimotoDepartment of Experimental and Clinical Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanTomomi IdeAuthorsSoichiro IkedaView author publicationsYou can also search for this author in PubMed聽Google ScholarShouji MatsushimaView author publicationsYou can also search for this author in PubMed聽Google ScholarKosuke OkabeView author publicationsYou can also search for this author in PubMed聽Google ScholarMasataka IkedaView author publicationsYou can also search for this author in PubMed聽Google ScholarAkihito IshikitaView author publicationsYou can also search for this author in PubMed聽Google ScholarTomonori TadokoroView author publicationsYou can also search for this author in PubMed聽Google ScholarNobuyuki EnzanView author publicationsYou can also search for this author in PubMed聽Google ScholarTaishi YamamotoView author publicationsYou can also search for this author in PubMed聽Google ScholarMasashi SadaView author publicationsYou can also search for this author in PubMed聽Google ScholarHiroko DeguchiView author publicationsYou can also search for this author in PubMed聽Google ScholarSachio MorimotoView author publicationsYou can also search for this author in PubMed聽Google ScholarTomomi IdeView author publicationsYou can also search for this author in PubMed聽Google ScholarHiroyuki TsutsuiView author publicationsYou can also search for this author in PubMed聽Google ScholarContributionsS.I. and S.M. proposed and designed the study; S.I., K.O., and S.M. performed experiments; A.I., T.T., N.E., T.Y. and T.T. analyzed data; S.I., S.M., M.I., M. S. and T.I. interpreted results of experiments; S.I. and H.D. prepared figures; S.I. drafted manuscript; S.I., S.M. and H.T. edited and revised manuscript; All authors approved final version of manuscript.Corresponding authorCorrespondence to Shouji Matsushima.Ethics declarations Competing Interests The authors declare no competing interests. Additional informationPublisher鈥檚 note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary information Sup fig and Fig legendRights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article鈥檚 Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article鈥檚 Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and PermissionsAbout this articleCite this articleIkeda, S., Matsushima, S., Okabe, K. et al. Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-魏B pathway. Sci Rep 9, 9850 (2019). https://doi.org/10.1038/s41598-019-46367-6Download citationReceived: 04 March 2019Accepted: 27 June 2019Published: 08 July 2019DOI: https://doi.org/10.1038/s41598-019-46367-6 CommentsBy submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Sign up for the Nature Briefing newsletter 鈥?what matters in science, free to your inbox daily.